Genedrive PLC Genedrive Assay used in STOP-HCV-1 Clinical Trial
10 August 2016 - 8:00AM
RNS Non-Regulatory
TIDMGDR
Genedrive PLC
10 August 2016
RNS Reach
For release: 10 August 2016
Genedrive(R) IL28B Genotyping Assay to be used in STOP-HCV-1
Clinical Trial
Genedrive plc (LSE: EHP), the near patient molecular diagnostics
company which recently changed its name from Epistem Holdings plc,
today announces that its Genedrive(R) point of care IL28B human
genotyping test will be used in the STOP-HCV-1 clinical trial being
run by STOP-HCV, a consortium designed to use stratified medicine
to optimise the treatment of patients with Hepatitis C Virus
infection. The trial is designed to assess the effectiveness of
different treatment durations with Direct Acting Antiviral (DAA)
treatments on Hepatitis C (HCV) genotype 1 patients
(http://www.stop-hcv.ox.ac.uk/stop-hcv-1-trial).
Direct Acting Antiviral (DAA) treatments are a new range of
drugs which are replacing interferon and other established
treatments for HCV. The new DAA treatments regimens are of a
shorter duration (12 weeks or less), are well tolerated and offer a
much improved chance of cure than earlier treatments. However,
costs remain high and, at present, there are no molecular
diagnostic tests to predict patients' response to treatment.
The STOP-HCV-1 clinical trial will assess two NICE approved DAA
treatment combinations and whether the addition of another, older
drug (ribavirin) has value in short course treatment. The project
is funded by the Efficacy and Mechanism Evaluation (EME) Programme,
an MRC and NIHR partnership. Around 400 patients are expected to be
recruited during 2016 and 2017. The aim is to discover which
patients may be cured by shorter courses of therapy and how new
techniques in molecular diagnostics, including the Genedrive(R)
IL28B point of care test, may be used to predict patient response.
Genedrive will provide 20 Genedrive(R) units and 400 tests for use
in the trial.
The Genedrive(R) test produces results within 50 minutes from a
simple cheek (buccal) swab compared to the standard approach which
uses a blood sample and which can have a service lab return time of
2-3 weeks for results. A recent clinical trial showed the
Genedrive(R) IL28B test was 100% accurate at detecting genetic
polymorphisms in HCV patients when compared with the current
'gold-standard' laboratory test.
Dr Graham Cooke, Chief Investigator of the STOP-HCV-1 clinical
trial, said: "We are pleased to incorporate the Genedrive(R) IL28B
point of care genotyping test in the STOP-HCV-1 clinical trial
which aims to identify key markers to guide the duration of
treatment required for HCV patients."
David Budd, CEO of Genedrive, commented: "The inclusion of our
Genedrive(R) IL28B genotyping test in the STOP-HCV-1 clinical
provides further validation of the potential of Genedrive(R) in
point of care genotype diagnostic testing.
If the STOP-HCV-1 clinical trial demonstrates that the IL28B
genotype is a reliable indication of patient response to shortened
DAA treatment, we would anticipate a role for the Genedrive(R)
IL28B test in future HCV treatments. The Genedrive(R) IL28B test
has been developed alongside the Genedrive(R) HCV test which is
scheduled for market launch in 2017."
- Ends -
For further details please contact:
Genedrive plc
David Budd: CEO +44 (0)161 989 0245
John Rylands: Finance Director
Peel Hunt LLP (NOMAD)
James Steel +44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
Genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point-of-need or point-of-care diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Genedrive(R) platform and MTB/RIF test have been
launched in India and a Genedrive(R) HCV test has been successfully
assessed by the Institut Pasteur, Paris.
Genedrive plc was formerly Epistem plc and continues to provide
contract research services to drug development companies under the
Epistem brand name.
Further details can be found at: www.genedriveplc.com and
www.genedrive.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAAKCDQDBKBKFK
(END) Dow Jones Newswires
August 10, 2016 02:00 ET (06:00 GMT)
Epistem (LSE:EHP)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Epistem (LSE:EHP)
Historical Stock Chart
Von Mai 2023 bis Mai 2024